CL2013003577A1 - Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas. - Google Patents

Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas.

Info

Publication number
CL2013003577A1
CL2013003577A1 CL2013003577A CL2013003577A CL2013003577A1 CL 2013003577 A1 CL2013003577 A1 CL 2013003577A1 CL 2013003577 A CL2013003577 A CL 2013003577A CL 2013003577 A CL2013003577 A CL 2013003577A CL 2013003577 A1 CL2013003577 A1 CL 2013003577A1
Authority
CL
Chile
Prior art keywords
ruxolitinib
panobinostat
prevention
treatment
pharmaceutical composition
Prior art date
Application number
CL2013003577A
Other languages
English (en)
Inventor
Fabienne Baffert
Thomas Radimerski
Brian Gadbaw
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003577(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2013003577A1 publication Critical patent/CL2013003577A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE PANOBINOSTAT Y RUXOLITINIB Y SU USO EN EL TRATAMIENTO Y /O PREVENCIÓN DE NEOPLASIA MIELOPROLIFERATIVA.
CL2013003577A 2011-06-14 2013-12-13 Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas. CL2013003577A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496750P 2011-06-14 2011-06-14
US201161568717P 2011-12-09 2011-12-09

Publications (1)

Publication Number Publication Date
CL2013003577A1 true CL2013003577A1 (es) 2014-08-01

Family

ID=47357438

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003577A CL2013003577A1 (es) 2011-06-14 2013-12-13 Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas.

Country Status (21)

Country Link
US (2) US20140113919A1 (es)
EP (1) EP2720696B1 (es)
JP (1) JP6200884B2 (es)
KR (1) KR20140056212A (es)
CN (1) CN103608012A (es)
AU (2) AU2012271814A1 (es)
BR (1) BR112013032125A2 (es)
CA (1) CA2844407A1 (es)
CL (1) CL2013003577A1 (es)
CO (1) CO6821954A2 (es)
EA (1) EA027654B1 (es)
ES (1) ES2595407T3 (es)
GT (1) GT201300308A (es)
HK (1) HK1193045A1 (es)
IL (1) IL229766A (es)
MX (1) MX344580B (es)
NZ (1) NZ618367A (es)
PE (1) PE20140604A1 (es)
SG (1) SG195141A1 (es)
WO (1) WO2012174061A1 (es)
ZA (1) ZA201308815B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
JP2015536964A (ja) * 2012-11-08 2015-12-24 ノバルティス アーゲー Ｂ−ｒａｆ阻害剤とヒストン脱アセチル化酵素阻害剤を含む医薬組合せおよび増殖性疾患の治療におけるそれらの使用
JP6479818B2 (ja) * 2013-05-10 2019-03-06 シーエヌアイシー ファンデーション セントロ ナショナル デ インベスティゲイショネス カーディオバスキュレアス カルロス ザ サード 骨髄増殖性新生物の治療に適した化合物
WO2015184087A2 (en) 2014-05-28 2015-12-03 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
WO2016026974A1 (en) * 2014-08-21 2016-02-25 Ratiopharm Gmbh Oxalate salt of ruxolitinib
WO2016047592A1 (ja) * 2014-09-22 2016-03-31 国立研究開発法人科学技術振興機構 抗インフルエンザウイルス剤、及び抗インフルエンザウイルス剤のスクリーニング方法
CZ2014773A3 (cs) * 2014-11-10 2016-05-18 Zentiva, K.S. Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
CA2982928A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
EP3298021B1 (en) 2015-05-18 2019-05-01 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs having increased bioavailability
WO2016196991A1 (en) * 2015-06-04 2016-12-08 Children's Hospital Medical Center Therapeutic targeting of myeloproliferative neoplasms by dusp1 inhibition
US10568887B2 (en) 2015-08-03 2020-02-25 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
WO2017196261A1 (en) * 2016-05-11 2017-11-16 National University Of Singapore Jak and hdac dual-inhibitor compounds
WO2017209766A1 (en) * 2016-06-03 2017-12-07 Q3 Medical Devices Limited Stent
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN112236139A (zh) * 2018-04-13 2021-01-15 大日本住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
KR20210098957A (ko) * 2018-09-25 2021-08-11 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
WO2020135401A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2021154976A1 (en) * 2020-01-28 2021-08-05 Secura Bio, Inc. Methods of treating brain cancer with panobinostat
CN111407894B (zh) * 2020-02-21 2022-04-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
EP2491923A3 (en) * 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
LT3070090T (lt) * 2007-06-13 2019-06-25 Incyte Holdings Corporation Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
EP2675451B9 (en) * 2011-02-18 2017-07-26 Novartis Pharma AG mTOR/JAK INHIBITOR COMBINATION THERAPY

Also Published As

Publication number Publication date
HK1193045A1 (zh) 2014-09-12
WO2012174061A1 (en) 2012-12-20
EA201490016A1 (ru) 2014-04-30
SG195141A1 (en) 2013-12-30
CN103608012A (zh) 2014-02-26
MX344580B (es) 2016-12-20
CO6821954A2 (es) 2013-12-31
KR20140056212A (ko) 2014-05-09
BR112013032125A2 (pt) 2016-12-13
EP2720696B1 (en) 2016-05-25
EA027654B1 (ru) 2017-08-31
AU2017204469A1 (en) 2017-07-20
NZ618367A (en) 2016-01-29
GT201300308A (es) 2017-09-28
JP6200884B2 (ja) 2017-09-20
ES2595407T3 (es) 2016-12-29
CA2844407A1 (en) 2012-12-20
US20180085371A1 (en) 2018-03-29
PE20140604A1 (es) 2014-05-13
EP2720696A1 (en) 2014-04-23
AU2012271814A1 (en) 2013-12-12
US20140113919A1 (en) 2014-04-24
ZA201308815B (en) 2014-07-30
JP2014517039A (ja) 2014-07-17
IL229766A0 (en) 2014-01-30
IL229766A (en) 2017-10-31
MX2013014805A (es) 2014-01-24

Similar Documents

Publication Publication Date Title
CL2013003577A1 (es) Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
ECSP11011557A (es) Mimético de smac
CL2015003507A1 (es) Beta-caseína a2 y prevención de inflamación del intestino
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
UY34829A (es) Nueva dosificación y formulación
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
DOP2010000361A (es) Dronedarona para la prevencion de la cardioversion
CL2016000397A1 (es) Tratamiento contra el cáncer
CL2011003248A1 (es) Composicion farmaceutica que comprende crf y un inhibidor de angiogenesis; util para la prevencion y el tratamiento del cancer.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
CL2016000179A1 (es) Formulación de combinación que contiene metformina de liberación prolongada e inhibidor de la hmg-coa reductasa de liberación inmediata.
GEP201706742B (en) Glycogen-based water solubility enhancers